Key Stats for UnitedHealth Stock
- Price change for UnitedHealth stock in Last 6 Months: 24%
- $UNH Share Price as of Jun. 30: $416
- 52-Week High: $428
- $UNH Stock Price Target: $412
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
UnitedHealth (UNH) stock is getting positive attention from Wall Street ahead of its Q2 earnings report on July 16. Morgan Stanley raised its price target on the stock to $468 from $453, implying about 13% upside from recent levels, while reiterating its top-pick status.
Analyst Erin Wright at Morgan Stanley said utilization commentary has turned “incrementally reassuring” throughout the quarter, which she sees as a good sign for managed care companies heading into Q2 earnings. She expects UnitedHealth to set a positive tone when it kicks off reporting on July 16.
Wright also flagged the company’s $1.5 billion investment in AI initiatives as a growing reason to own the stock. She expects AI proof points to become increasingly important for UnitedHealth stock as the year progresses.
Bernstein SocGen Group is equally optimistic. The firm reiterated its Outperform rating with a $492 price target, expecting Q2 adjusted EPS of $5.22, well above the $4.84 consensus estimate.
Bernstein also expects a medical loss ratio of 88.0%, better than the 88.5% consensus, and believes UnitedHealth could raise its full-year guidance above current expectations.
See analysts’ growth forecasts and price targets for UnitedHealth stock (It’s free) >>>
What the Market Is Telling Us About UnitedHealth Stock
UnitedHealth stock is up 24% this year, significantly outpacing the broader S&P 500. Shares are trading near their 52-week high, and multiple analysts view the current valuation as attractive given what they expect to be a multi-year earnings recovery.
The investment thesis centers on Medicare Advantage recovering from a period of trough margins following rate pressures and reduced competition. UnitedHealth is also exiting unprofitable Medicare Advantage and Optum Health contracts, which should improve margins over time.
The Q1 2026 results gave investors a reason for optimism.
- The company reported adjusted earnings per share of $7.23, well ahead of expectations, with all major business segments exceeding their internal plans.
- Optum Health showed particularly strong improvement, with medical cost management and operational execution both trending in the right direction.
- The company also updated its full-year adjusted EPS guidance to greater than $18.25.
Not everything is smooth sailing. TD Cowen lowered its price target to $197 from $230, citing lower core growth estimates and challenges related to behavioral health licensure, while maintaining a Buy rating.
Still, UnitedHealth stock remains one of the most closely watched names in health care, and with Q2 earnings just weeks away, the setup is looking increasingly constructive according to the bulls.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does UnitedHealth Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
